We serve Chemical Name:3-(Hexylsulfamoyl)benzoic acid CAS:500292-07-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(Hexylsulfamoyl)benzoic acid
CAS.NO:500292-07-9
Synonyms:3-(Hexylsulfamoyl)benzoic acid
Molecular Formula:C13H19NO4S
Molecular Weight:285.35900
HS Code:2935009090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:91.85000
Exact Mass:285.10300
LogP:3.71510
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-(Hexylsulfamoyl)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Hexylsulfamoyl)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(Hexylsulfamoyl)benzoic acid Use and application,3-(Hexylsulfamoyl)benzoic acid technical grade,usp/ep/jp grade.
Related News: A possible reason for this is that developments within the biocatalysis field have fast outpaced existing knowhow, leaving some pharmaceutical companies unaware of the vast range of options available. Keeping abreast of both current and emerging developments within the field of biocatalytic processing is key when it comes to maintaining a competitive edge. UNII:81065MP285 manufacturers A thorough safety and risk analysis procedure should be administered at an appropriate time with documentation that adheres to the rules and regulations set forth by the regulatory authorities. 3-(1-aminoethyl)-N,N-dimethylaniline suppliers The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 3-Fluoro-2H-indazole vendor & factory In 2018, the Bengaluru-based Natural Capsules set up an R&D centre in at Attibele, Bengaluru. In 2020, when PLI scheme was announced it applied for the same. ,A possible reason for this is that developments within the biocatalysis field have fast outpaced existing knowhow, leaving some pharmaceutical companies unaware of the vast range of options available. Keeping abreast of both current and emerging developments within the field of biocatalytic processing is key when it comes to maintaining a competitive edge.
